ES
Elizabeth Schmitz
University of Nebraska Medical Center, Nebraska Cancer Specialists, University of Nebraska–Lincoln
Research areas: Medicine · Hematology · Chronic Lymphocytic Leukemia Research · Lymphoma Diagnosis and Treatment · Gut microbiota and health
0000-0002-9619-5193
Employment
-
University of Nebraska Medical Center Graduate Research Assistant2024 - Present
-
University of Nebraska Medical Center Graduate Researcher2022 - 2024
-
Nebraska Cancer Specialists Medical Scribe/Patient-care-coordinating2020 - 2024
-
University of Nebraska-Lincoln Undergraduate researcher2019 - 2021
Education
- 2024 - 2032
- 2022 - 2024
-
University of Nebraska - Lincoln BA in Biology2015 - 2019
-
University of Nebraska-Lincoln BS in Biochemistry2015 - 2019
Projects & Funding
Projects & funding information is unavailable.
Publications (42)
- Data from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Figure 1 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Figure 2 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Figure 3 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Figure 4 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Figure 5 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Figure 6 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Figure 7 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Figure S1 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Figure S2 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Figure S3 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Figure S4 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Figure S5 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Figure S6 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Figure S7 from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Supplementary Methods from Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- Gut Microbiome Profiling in Eμ-TCL1 Mice Reveals Intestinal Changes and a Dysbiotic Signature Specific to Chronic Lymphocytic Leukemia Save
- BET Protein Inhibition Relieves MDSC-Mediated Immune Suppression in Chronic Lymphocytic Leukemia Save
- Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3 Save
- Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3 Save